Edition:
India

Cipher Pharmaceuticals Inc (CPH.TO)

CPH.TO on Toronto Stock Exchange

1.16CAD
24 Sep 2020
Change (% chg)

-- (--)
Prev Close
$1.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,998
52-wk High
$1.68
52-wk Low
$0.38

Summary

Name Age Since Current Position

Craig Mull

2019 Chairman of the Board

Robert Tessarolo

2017 President, Chief Executive Officer

Nadine Jutlah

2019 Interim Chief Financial Officer

Ralph Bohrer

54 2016 President and General Manager of US Business

Joan Chypyha

2015 President, General Manager - Canada

Joseph Pecora

2015 President and General Manager - USA

Lorne Markowitz

2015 Vice President of Sales and Marketing

Linda Angaritis

2015 Vice President - Global Regulatory Compliance and Quality

Louise Blythe

2015 Vice President - Regulatory Affairs

Lynne Bulger

2015 Vice President - Medical and Clinical Affairs

Michael Milloy

2018 Vice President - Canadian commercial operations

Brian Rosenberger

2015 Vice President - Alliance and Strategic Portfolio Management

Peter Weiler

2015 Vice President - Business Development

Christian Godin

2016 Director

John Mull

83 2019 Director

Harold Wolkin

66 2016 Director

Stefan Aigner

50 2007 Independent Director

Thomas Wellner

51 2014 Independent Director

Stephen Wiseman

70 2005 Independent Director

Biographies

Name Description

Craig Mull

Mr. Craig J. Mull is Chairman of the Board of the Company. Mr. Mull has extensive experience in the Canadian healthcare industry, including holding the position of COO with CML HealthCare where he was responsible for the day-to-day operations. During his tenure at CML, Mr. Mull was part of a small executive team that grew the company from a market cap of $100 million to over $1.2 billion. Mr. Mull also played an integral role in planning and structuring Cipher's initial public offering as it was spun out of CML.

Robert Tessarolo

Mr. Robert D. Tessarolo has been appointed as President, Chief Executive Officer of the Company, effective April 17, 2017. Mr. Tessarolo most recently held the position of vice-president and general manager with Celgene Corp., where he was responsible for leading its U.S. inflammation and immunology business. He contributed to the substantial expansion of the U.S. business in 2016, which was led by the rapid growth of Otezla for plaque psoriasis and psoriatic arthritis. Prior to Celgene, Mr. Tessarolo led the launch of Actavis PLC's Canadian specialty pharmaceutical division and served as president and general manager. Under his leadership, Mr. Tessarolo established a Canadian business of over 140 employees and $190-million in revenues, leading his team through several new product launches and the successful integration of multiple company acquisitions, including Warner Chilcott, Forest Labs and Allergan. Prior to joining Actavis, Mr. Tessarolo held a number of positions of increasing responsibility with Biovail Pharmaceuticals Canada, culminating in his appointment to the position of vice-president and general manager. Mr. Tessarolo had direct oversight and accountability for country strategy, operations, business development and financial responsibilities for each of the Canadian entities he has led. Mr. Tessarolo serves on the board of directors of Bradmer Pharmaceuticals. He is a graduate of Carleton University with a BA in economics and has attended the advanced management program for general management at Ross School of Business at the University of Michigan.

Nadine Jutlah

Ms. Nadine Jutlah, CPA is appointed as Interim Chief Financial Officer of the Company., effective March 29, 2019. Ms. Jutlah has been a senior finance executive at Cipher for over two years and has done an extraordinary job leading the Company's finance team. Prior to joining the Company, Ms. Jutlah worked at Ernst & Young LLP for 13 years holding positions with increasing responsibilities, departing as a senior manager. Ms. Jutlah is a Chartered Professional Accountant (CPA, CA) and has a Master of Science in Accounting from Frank Sawyer School of Management at Suffolk University, Boston, Massachusetts.

Ralph Bohrer

Mr. Ralph Bohrer is President and General Manager of US Business of the Company. Prior to joining Cipher, he was executive director, sales and marketing, of Taro Pharma, a global leader in the development, manufacture and sale of dermatology products. In this role, he was responsible for all aspects of its branded dermatology business unit for Taro Pharmaceutical Industries. Previously, he was vice-president, sales, at Triax Pharmaceuticals (acquired by PreCision Dermatology in 2012), where he led a 60-person team responsible for the promotion and sale of a line of prescription dermatology products, including category leader Locoid lipocream and lotion, Tretin X, and Minocin.

Joan Chypyha

Ms. Joan Chypyha has been promoted as President, General Manager - Canada of the Company. She was Vice President - Marketing and Sales of the company. She has more than 25 years in the pharmaceutical industry with an emphasis on marketing, sales and business development. Previously Ms. Chypyha was Chief Development Officer of Rhei Pharmaceuticals Ltd.; Vice President, Corporate Development at Barrier Therapeutics Inc.; General Manager of Barrier Therapeutics Canada Inc; and Founder of Alto Pharmaceuticals Ltd. She also spent 16 years with Hoffman-La Roche in several progressively senior positions, including Business Unit Director, Dialysis and PPN and Business Unit Director, Dermatology. In this role, Ms. Chypyha was responsible for the management of a specialty sales force that represented Accutane, among other brands. Ms. Chypyha received her Bachelor of Science from University of Toronto and completed an Executive MBA from Queen’s University.

Joseph Pecora

Mr. Joseph Pecora has been promoted as President and General Manager - USA of the Company. Mr. Pecora joined Cipher's leadership team in April 2014 through the acquisition of Innocutis Holdings Inc., of which he was the founder and President and CEO, and where he led the company's sales force and marketing and business development functions. During his tenure, he acquired the rights to Nuvail(R) in 2013, a market leader in nail dystrophy, and Sitavig(R), a treatment for cold sore outbreaks in 2014.

Lorne Markowitz

Mr. Lorne Markowitz is Vice President of Sales and Marketing of Cipher Pharmaceuticals Inc. Mr. Markowitz is a 35-year sales and marketing veteran in the Canadian pharmaceutical industry, including tenures as vice-president of dermatology at Valeant Canada and vice-president, sales and marketing, at Leo Pharma.

Linda Angaritis

Ms. Linda Angaritis has been appointed as Vice President - Global Regulatory Compliance and Quality of Cipher Pharmaceuticals Inc., with effect from 19 January 2015. Ms. Angaritis joined Cipher in 2013 and is responsible for the overall regulatory compliance and quality functions across the business.

Louise Blythe

Ms. Louise Blythe is Vice President - Regulatory Affairs of the Company. Ms. Blythe brings to Cipher 16 years' of experience in Regulatory Affairs in the pharmaceutical industry. Most recently, she served as Director of Regulatory Affairs and Quality Assurance at Forest Laboratories Canada Inc., where she was instrumental in establishing Forest Laboratories' Canadian subsidiary and building the Regulatory and Quality Assurance department. Prior thereto, she held various positions of increasing responsibility within Regulatory Affairs at AstraZeneca Canada Inc., including head of strategic product development and lifecycle management.

Lynne Bulger

Ms. Lynne Bulger has been appointed as Vice President - Medical and Clinical Affairs of Cipher Pharmaceuticals Inc., with effect from 19 January 2015. Ms. Bulger has 27 years of experience in drug development in the pharmaceutical industry, conducting clinical research and providing strategic medical marketing support in dermatology, rheumatology, osteoporosis and CNS. Most recently, Ms. Bulger held the position of Director Medical Affairs at Stiefel, a GSK company. In this role, she was responsible for medical affairs activities for Stiefel Global and Canada for 35 dermatology products. Previously, Ms. Bulger was Director Medical and Regulatory Affairs at Barrier Therapeutics and Director Medical Affairs at Hoffman-La Roche. She served as President of the Canadian Dermatology Industry Association from 2005 to 2008.

Michael Milloy

Mr. Michael Milloy is Vice President - Canadian commercial operations of the company. Prior to joining Cipher, Mr. Milloy, held the position of Business Unit Head, Neurology & Immunology with EMD Serono, where he was responsible for the executive leadership and strategic direction to a business unit growing at an annual growth rate of 30%. Prior to working at EMD Serono, Mr. Milloy held senior positions at Biogen Canada and Takeda Canada. Mr. Milloy holds a BA Psychology, BSc Biology and an Executive MBA with a specialty in General Management.

Brian Rosenberger

Mr. Brian Rosenberger is Vice President - Alliance and Strategic Portfolio Management of the Company. Mr. Rosenberger brings to Cipher over two decades' experience in the biopharmaceutical industry, specifically in specialty markets, having served in leadership roles across a variety of areas, including marketing, sales, market research, business development, portfolio management and alliance management. He joins Cipher from Auxilium Pharmaceuticals Inc., where he was initially responsible for marketing the company's flagship brand, Testim(R), a testosterone gel. Most recently, he held a dual role, which included running the Alliance Management function across numerous global partners, as well as managing the company's Business Development activities.

Peter Weiler

Mr. Peter Weiler has been appointed as Vice President - Business Development of Cipher Pharmaceuticals Inc., with effect from 19 January 2015. Mr. Weiler has been with Cipher since 2008 and leads the Company's expanding business development activities.

Christian Godin

Mr. Christian Godin is Director of the Company. He is Head of Equities at Montrusco Bolton Investments Inc. and sits on its board of directors. He is also a member of the Management Committee of Montrusco. Montrusco is aMontreal-based investment firm that has approximately$6.0 billionin assets under management. Prior to joining Montrusco in 2001, Christian worked for Merrill Lynch Canada where he was a director and senior equity research analyst. He also worked for Midland Walwyn Capital and CTI Capital. Christian holds a Bachelor of Business Administration from Université du Québec à Montréal and a Master of Science in Administration specialized in Finance from HEC Montréal.

John Mull

Dr. John D. Mull, M.D. is Director of the Company. He was Independent Director of Cipher Pharmaceuticals Inc. Dr. Mull is currently the Chief Executive Officer of Typhon Group Limited, a private equity capital corporation. Dr. Mull is the founder and until August 8, 2006 was the Chief Executive Officer of both Cipher and CML HealthCare Inc. (“CML”). Dr. Mull is also the founder and former Chief Executive Officer of Pharma Medica Research Inc. (“Pharma Medica”) and Starplex Scientific, Inc. (“Starplex”). In those capacities, he has overseen the operations of significant enterprises and been involved in more than thirty merger and acquisition transactions. Cipher and Pharma Medica were subsidiaries of CML prior to CML’s conversion to an income trust in 2004. At the time, CML was one of the largest operators of medical diagnostic and medical imaging facilities in Canada and in the United States. Its peak market capitalization exceeded $1.4 billion. CML merged with LifeLabs Medical Laboratory Services (“LifeLabs”) in 2013. Pharma Medica is a contract research organization that provides services to pharmaceutical and other life science companies. Starplex develops and manufactures innovative medical devices. Dr. Mull is a graduate of the Faculty of Medicine, University of Toronto, and completed his training in Anatomic and Clinical Pathology at the University of Michigan (Ann Arbor). He is certified in Pathology by the Royal College of Physicians and Surgeons and in Anatomic and Clinical Pathology by the American College of Physicians and Surgeons. His original investigative research work in those fields involved publication of 15 papers in various medical journals.

Harold Wolkin

Mr. Harold M. Wolkin is Director of the Company. He is an accomplished investment banker and financial analyst with over 30 years of experience. Mr. Wolkin joined BMO Nesbitt Burns as a senior research analyst in 1983. He went on to serve as managing director in the Diversified Industries Group of BMO Capital Markets untilJanuary 2008. Most recently, Mr. Wolkin served as Executive Vice-President and Head of Investment Banking for Dundee Capital Markets. Mr. Wolkin has served on a number of public company and not-for-profit boards and currently serves as a director of Diamond Estates Wines & Spirits and Baylin Technologies Inc. He was the past President of the CFA Society ofTorontoand has been a member of the Chartered Financial Institute since 1980. He is a member of the Institute of Corporate Directors.

Stefan Aigner

Dr. Stefan Aigner, M.D., CFA, is an Independent Director of Cipher Pharmaceuticals Inc. Dr. Aigner is a founder of Inspirion Pharmaceuticals, LLC, a company formed in 2006 to pursue opportunities in the specialty pharmaceutical industry and Inspirion Delivery Technologies, LLC, a company formed in 2008 to pursue abuse deterrent product development, and has been principally occupied in that role since May 2008. From 2006 until 2008 Dr. Aigner was the Executive Vice-President, Corporate and Business Development at Alpharma, Inc. (“Alpharma”) a global specialty pharmaceutical company. Before joining Alpharma, Dr. Aigner was co-founder and Executive Vice President of Business Development and Medical Affairs for Reliant Pharmaceuticals, Inc. (“Reliant”) a pharmaceutical company that specializes in the development, commercialization and marketing of prescription therapeutic products. Dr. Aigner served at Reliant from 1999 to 2006. During his tenure at Reliant, Dr. Aigner led the company through multiple acquisitions and significant inlicensing transactions and was responsible for building the company’s cardiovascular portfolio through partnerships with leading U.S. and European companies. Prior to working at Reliant, Dr. Aigner was a consultant with healthcare consulting firm The Wilkerson Group from 1996 to 1999. Dr. Aigner graduated summa cum laude with a degree in medicine from the University of Erlangen, Nuremberg, Germany.

Thomas Wellner

Mr. Thomas G. Wellner is an Independent Director of Cipher Pharmaceuticals Inc. Most recently, He is CEO of Revera Inc., is a leading provider of seniors’ accommodation, care and services. Revera is owned by The Public Sector Pension Investment Board (PSP Investments) is one of Canada’s largest pension investment managers, with $76.1 billion of assets under management at March 31, 2014. With his holding company, WellCap Advisors Limited, Tom is also involved in providing strategic guidance to a number of clients and also investing in healthcare and technology companies. Previously, Mr. Wellner was co-Chief Executive Officer of LifeLabs, Canada’s largest laboratory services company, where he was responsible for leading the integration of CML HealthCare Inc. (“CML”) into LifeLabs’ organization. Prior to LifeLabs, Mr. Wellner was President and Chief Executive Officer of CML, where he led the company through a strategic re-assessment prior to its merger with LifeLabs. Before CML, Tom spent 20 years with Eli Lilly & Company in a variety of senior operational and strategic leadership roles in Canada, China, United States, Latin America, Europe, and the United Kingdom. Tom has also worked with private equity on a startup as President and CEO of Therapure Biopharma, a privately held bio-manufacturing and drug development company. Mr. Wellner currently sits on the boards of DiaMedica Inc. (TSX:DMA), FreshBooks, Inc. (private) and Atlantic Healthcare Plc (private-UK). Tom is also a Board member of Life Sciences Ontario (LSO – Industry Association). He is also on the Board of Governors of Rothesay Netherwood School, a private Atlantic Canadian boarding school since November 2011. Further, Tom has served on the editorial committee for Pharmaceutical Marketing Europe, and has led business cases at INSEAD and Harvard Business School.

Stephen Wiseman

Mr. Stephen R. Wiseman is Independent Director of Cipher Pharmaceuticals Inc. Mr. Wiseman was Chair of the Board of CML HealthCare Inc. until March 3, 2011. He was previously a partner of Taylor Leibow LLP, the largest independent accounting firm in the greater Hamilton and Burlington region and he continues to serve as an advisor and consultant with the firm. Mr. Wiseman is a member of the Canadian Institute of Chartered Accountants and the Institute of Chartered Accountants of Ontario. In addition, he holds a CMA designation from the Society of Management Accountants of Ontario and a CFE designation from the Association of Certified Fraud Examiners. Prior to joining Taylor Leibow in 1976, Mr. Wiseman held academic positions at McMaster University, University of Saskatchewan and University of Ottawa. He earned his MBA from McMaster University and Bachelor of Commerce and Master of Arts (Economics) degrees from the University of Ottawa. Mr. Wiseman serves as Chair of Cipher’s Audit Committee.